Pharmaceutical intermediates
Lenacapavir sodium Intermediates
4 pharmaceutical intermediates for Lenacapavir sodium. Indication: HIV.
About Lenacapavir sodium
- Originator
- Gilead Inc
- Indication
- HIV
- Approved Date
- 12/22/2022
- NCE Patent
- 12/22/2027
- DS/DP
- 02/28/2034
Available intermediates
4 intermediates currently listed for Lenacapavir sodium. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid | 1620056-83-8 | / | / |
| 4-Chloro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indazol-3-amine | 2189684-53-3 | / | / |
| 3-Methyl-3-(methylsulfonyl)but-1-yne | 2109226-54-0 | / | / |
| Carbamic acid, N-[(1S)-1-(3,6-dibromo-2-pyridinyl)-2-(3,5-difluorophenyl)ethyl]-, 1,1-dimethylethyl ester | 1620056-47-4 | / | / |
Building toward Lenacapavir sodium?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →